Pioneering a New Chapter in Omnichannel Marketing for Multiple Products: Qizheng Tibetan Medicine Sees 34.41% Growth in Net Profit for the First Half of the Year

On the evening of August 24, Qizheng Tibetan Medicine disclosed its semiannual report. In the first half of this year, the company embarked on a new chapter of comprehensive marketing across multiple product lines. During the reporting period, the company achieved operating revenue of 829 million yuan, a decrease of 7.48% compared to the same period last year; net profit attributable to shareholders of the listed company reached 312 million yuan, an increase of 34.41% over the same period last year; and basic earnings per share amounted to 0.5893 yuan.

2023 marked the inaugural year of Qizheng Tibetan Medicine’s “Dual-Drive, Dual-Leading, Dual-Foundation” strategy. In terms of products, the company offers integrated pain management solutions to patients through a diversified product portfolio, striving to become the leading brand in the field of topical analgesics and creating value for its customers. At the same time, guided by clinical value, the company is further expanding its product lineup into seven key therapeutic areas: respiratory, dermatological, pediatric, gynecological, digestive, cardiovascular, and neurological. During the reporting period, Qizheng Tibetan Medicine’s Xiaotong Paste received the honor of “2022 China Over-the-Counter Drug Golden Best-Selling Product,” was recognized as an influential brand in China’s pharmaceutical industry, and was included in the 2023 Retail Terminal “China Pharmaceutical·Brand List.” The company has built a comprehensive pain relief product line centered around Xiaotong Paste, Bai Mai Ointment, Qing Peng Ointment, and Ruyi Zhenbao Tablets, achieving a transition from single-product offerings to a diversified product portfolio—including patch, ointment, and oral dosage forms—and thereby establishing an integrated treatment model for musculoskeletal pain management.

In terms of channels, the company is pursuing a strategy centered on "strengthening pain management, expanding grassroots healthcare coverage, exploring new areas, and attracting investment with precision," thereby enhancing both the breadth and depth of its product reach in tiered medical care and primary healthcare settings. While broadening the market for pain management products, the company is also venturing into the women’s and children’s health sectors and nurturing growth in the respiratory and digestive markets. In the B2C channel, through brand strategy diagnostics and identification of target audiences, the company is focusing on core strategic segments, increasing brand exposure both on and off its platform, optimizing in-platform operations, and improving communication and conversion efficiency. During the “618” shopping festival, the company added over 1.6 million new users to its brand equity pool, while the natural user search-to-purchase conversion rate improved by more than 5%. In the O2O channel, leveraging effective platform tools, the company is precisely targeting labeled users to drive purchases and boost repeat purchase rates. By harnessing platform big data, the company is collaborating closely with key chain stores and new retail platforms to efficiently and accurately enhance the accessibility of its flagship products. Thanks to its steady growth, the company has been included in the "Top 100 Chinese Traditional Chinese Medicine Enterprises Ranking" and has risen to 29th place.

In the first half of the year, Qizheng Tibetan Medicine donated a total of 3.214 million yuan, continuing to support poverty alleviation efforts in areas such as education, health, and special-purpose assistance. Specifically, the company implemented six projects—including supporting grassroots Tibetan medical education, providing student aid, offering free health consultations, and providing assistance for serious illnesses—primarily benefiting charitable and public welfare initiatives in western regions such as Tibet, Qinghai, and Gansu. As of the end of the first half of the year, the company held 147 patented technologies, including 129 invention patents.

Reporting media: Shanghai Securities Journal · China Securities Network

Report link: https://ggjd.cnstock.com/company/scp_ggjd/tjd_bbdj/202308/5112059.htm